Equilis West Nile
inactivated chimaeric flavivirus strain YF-WN
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Equilis West Nile
|
Agency product number |
EMEA/V/C/002241
|
Active substance |
inactivated chimaeric flavivirus strain YF-WN
|
International non-proprietary name (INN) or common name |
inactivated chimaeric flavivirus strain YF-WN
|
Species |
Horses
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI05AA10
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
2
|
Date of issue of marketing authorisation valid throughout the European Union |
06/06/2013
|
Contact address |
Wim de Körverstraat 35
5831 AN Boxmeer Netherlands |
Product information
03/10/2018 Equilis West Nile - EMEA/V/C/002241 - IB/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of horses against West Nile virus (WNV) to reduce clinical signs of disease and lesions in the brain and to reduce viraemia.
Onset of immunity: 2 weeks after primary vaccination course of two injections.
Duration of immunity: 12 months.